Substituted 5-fluoro-1h-pyrazolopyridines and their use

Abstract

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

1 . A compound of the formula (I) 
       
         
           
           
               
               
           
         
       
       in which
 R 1  represents hydrogen or (C 1 -C 4 )-alkyl,
 where (C 1 -C 4 )-alkyl may be substituted by one or two substituents independently of one another selected from the group consisting of fluorine and trifluoromethyl, 
 
 
       and N-oxides, salts, solvate salts of the N-oxides and solvates of the N-oxides and salts thereof. 
     
     
         2 . The compound  claim 1  in which
 R 1  represents hydrogen or methyl,
 where methyl may be substituted by a trifluormethyl substitutent, 
 
 
       and salts, solvates and solvates of the salts thereof. 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . A medicament comprising the compound of  claim 1  in combination with an inert, non-toxic, pharmaceutically suitable excipient. 
     
     
         9 . A medicament comprising the compound of  claim 1  in combination with a further active compound selected, from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors, agents having antithrombotic activity, agents lowering blood pressure, and agents altering lipid metabolism. 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . A method of treating or preventing heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, kidney failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis comprising administering an effective amount of the compound of  claim 1  to a human or animal in need thereof.